Not Tagged
Not Tagged
['biomarker', 'sclc']
there was a modest pfs benefit and so this is a positive trial. but the benefit was quite modest and considering no os benefit and toxicity with parpi, hard to consider this practice changing. main success is in biomarker-driven therapy for #sclc, which was impressive. #asco23 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast, #ITYSL, #HereWeGo